Flash FinanceUS
After hours S&P 5007,520.93-0.38% Nasdaq25,065.88-0.74% Dow 3052,231.89-0.30% Russell 20002,821.38-0.68% Nasdaq-10027,740.79-0.60% MidCap 4003,700.81-0.39% SmallCap 6001,716.22-0.36% VIX19.46-2.31% 10Y Yield4.98+2.45% Close of Nov 10, 2026
AI brief of an SEC Form 8-K · InMed Pharmaceuticals Inc. (MTRI)

InMed completes merger with Mentari, renamed Mentari Therapeutics, Inc.

Mixed Impact 5 of 5 m&a

InMed Pharmaceuticals completed its merger with Mentari Therapeutics on November 6, 2026, and InMed changed its name to Mentari Therapeutics, Inc. InMed securityholders before the merger are expected to own approximately 1.0% of the combined company on a fully diluted basis, while Mentari securityholders, including pre-closing financing investors, are expected to own approximately 99.0%. Pre-merger InMed legacy cannabinoid assets were moved to a contingent value rights arrangement, and the company stated it does not expect to continue material development of those programs.

Key points

  • Merger closed November 6, 2026, after a 1-for-10 reverse stock split of InMed common stock, with an Exchange Ratio of 0.20065 shares per Mentari common share.
  • Mentari pre-closing financing raised aggregate gross proceeds of approximately $490.0 million, including $52.7 million of principal and accrued interest on convertible notes.
  • InMed securityholders are expected to own approximately 1.0% of the combined company on a fully diluted basis.
  • Holders of record of InMed common stock as of November 5, 2026 received one contingent value right per share tied to net proceeds from legacy assets.

The filing

CompanyInMed Pharmaceuticals Inc. (MTRI)
Form8-K, current report
Filed with the SECNov 10, 2026, 4:45 PM ET
Accession number0001193125-26-455640

Items reported: 1.01 Material Definitive Agreement2.01 Acquisition or Disposition Completed2.02 Results of Operations3.02 Unregistered Equity Sale3.03 Change to Shareholder Rights5.01 Change in Control5.02 Director / Officer Change5.03 Bylaw / Charter Amendment5.05 Code of Ethics Change5.06

Read the filing on SEC.gov ↗

Written by AI on Nov 10, 2026, 4:55 PM ET, from this filing only.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.